Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 31 May 1985:
Vol. 228. no. 4703, pp. 1115 - 1117
DOI: 10.1126/science.3992249
Prev | Table of Contents | Next

Articles

Science, Vol 228, Issue 4703, 1115-1117
Copyright © 1985 by American Association for the Advancement of Science

articles

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation

DC Mash, DD Flynn, and LT Potter

Cerebral cortex samples from patients with Alzheimer's disease and from rats after experimental cholinergic denervation of the cerebral cortex exhibited reductions in the presynaptic marker choline acetyltransferase activity and in the number of M2 muscarine receptors, with no change in the number of M1 receptors. These results are in keeping with evidence that M2 receptors function in cholinergic nerve terminals to regulate the release of acetylcholine, whereas M1 receptors are located on postsynaptic cells and facilitate cellular excitation. New M1-selective agonists and M2-selective antagonists directed at post- or presynaptic sites deserve consideration as potential agents for the treatment of the disease.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
G Protein-Coupled Receptors, Cholinergic Dysfunction, and A{beta} Toxicity in Alzheimer's Disease.
A. Thathiah and B. De Strooper (2009)
Science Signaling 2, re8
   Abstract »    Full Text »    PDF »
Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder.
S. Cohen-Woods, D. Gaysina, N. Craddock, A. Farmer, J. Gray, C. Gunasinghe, F. Hoda, L. Jones, J. Knight, A. Korszun, et al. (2009)
Hum. Mol. Genet. 18, 1504-1509
   Abstract »    Full Text »    PDF »
CHRM2 variation predisposes to personality traits of agreeableness and conscientiousness.
X. Luo, H. R. Kranzler, L. Zuo, H. Zhang, S. Wang, and J. Gelernter (2007)
Hum. Mol. Genet. 16, 1557-1568
   Abstract »    Full Text »    PDF »
Pre- and Poststimulus Alpha Rhythms Are Related to Conscious Visual Perception: A High-Resolution EEG Study.
C. Babiloni, F. Vecchio, A. Bultrini, G. Luca Romani, and P. M. Rossini (2006)
Cereb Cortex 16, 1690-1700
   Abstract »    Full Text »    PDF »
CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study.
X. Luo, H. R. Kranzler, L. Zuo, S. Wang, H. P. Blumberg, and J. Gelernter (2005)
Hum. Mol. Genet. 14, 2421-2434
   Abstract »    Full Text »    PDF »
M2 Muscarinic Acetylcholine Receptor Knock-Out Mice Show Deficits in Behavioral Flexibility, Working Memory, and Hippocampal Plasticity.
T. Seeger, I. Fedorova, F. Zheng, T. Miyakawa, E. Koustova, J. Gomeza, A. S. Basile, C. Alzheimer, and J. Wess (2004)
J. Neurosci. 24, 10117-10127
   Abstract »    Full Text »    PDF »
A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease.
P M Kemp, C Holmes, S Hoffmann, S Wilkinson, M Zivanovic, J Thom, L Bolt, J Fleming, and D G Wilkinson (2003)
J. Neurol. Neurosurg. Psychiatry 74, 1567-1570
   Abstract »    Full Text »    PDF »
Characterization of Central Inhibitory Muscarinic Autoreceptors by the Use of Muscarinic Acetylcholine Receptor Knock-Out Mice.
W. Zhang, A. S. Basile, J. Gomeza, L. A. Volpicelli, A. I. Levey, and J. Wess (2002)
J. Neurosci. 22, 1709-1717
   Abstract »    Full Text »    PDF »
Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex.
M. K. P. Lai, O. -F. Lai, J. Keene, M. M. Esiri, P. T. Francis, T. Hope, and C. P.L.-H. Chen (2001)
Neurology 57, 805-811
   Abstract »    Full Text »    PDF »
Synthesis and Pharmacological Evaluation of Dimeric Muscarinic Acetylcholine Receptor Agonists.
A. Christopoulos, M. K. O. Grant, N. Ayoubzadeh, O. N. Kim, P. Sauerberg, L. Jeppesen, and E. E. El-Fakahany (2001)
J. Pharmacol. Exp. Ther. 298, 1260-1268
   Abstract »    Full Text »    PDF »
Muscarinic Cholinergic Modulation of Prepulse Inhibition of the Acoustic Startle Reflex.
C. K. Jones and H. E. Shannon (2000)
J. Pharmacol. Exp. Ther. 294, 1017-1023
   Abstract »    Full Text »
Pharmacological Characterization of Endogenous Acetylcholine Release from Primary Septal Cultures.
D. S. Auld, J. C. Day, F. Mennicken, and R. Quirion (2000)
J. Pharmacol. Exp. Ther. 292, 692-697
   Abstract »    Full Text »
The M1 Muscarinic Agonist CI-1017 Facilitates Trace Eyeblink Conditioning in Aging Rabbits and Increases the Excitability of CA1 Pyramidal Neurons.
C. Weiss, A. R. Preston, M. M. Oh, R. D. Schwarz, D. Welty, and J. F. Disterhoft (2000)
J. Neurosci. 20, 783-790
   Abstract »    Full Text »    PDF »
Milameline (CI-979/RU35926): A Muscarinic Receptor Agonist with Cognition-Activating Properties: Biochemical and In Vivo Characterization.
R. D. Schwarz, M. J. Callahan, L. L. Coughenour, M. R. Dickerson, J. J. Kinsora, W. J. Lipinski, C. A. Raby, C. J. Spencer, and H. Tecle (1999)
J. Pharmacol. Exp. Ther. 291, 812-822
   Abstract »    Full Text »
M2 Muscarinic Autoreceptors Modulate Acetylcholine Release in the Medial Pontine Reticular Formation.
H. A. Baghdoyan, R. Lydic, and M. A. Fleegal (1998)
J. Pharmacol. Exp. Ther. 286, 1446-1452
   Abstract »    Full Text »
On the Unique Binding and Activating Properties of Xanomeline at the M1 Muscarinic Acetylcholine Receptor.
A. Christopoulos, T. L. Pierce, J. L. Sorman, and E. E. El-Fakahany (1998)
Mol. Pharmacol. 53, 1120-1130
   Abstract »    Full Text »
SB 202026: A Novel Muscarinic Partial Agonist with Functional Selectivity for M1 Receptors.
J. M. Loudon, S. M. Bromidge, F. Brown, M. S. G. Clark, J. P. Hatcher, J. Hawkins, G. J. Riley, G. Noy, and B. S. Orlek (1997)
J. Pharmacol. Exp. Ther. 283, 1059-1068
   Abstract »    Full Text »
Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease.
N. C. Bodick, W. W. Offen, A. I. Levey, N. R. Cutler, S. G. Gauthier, A. Satlin, H. E. Shannon, G. D. Tollefson, K. Rasmussen, F. P. Bymaster, et al. (1997)
Arch Neurol 54, 465-473
   Abstract »    PDF »
Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure Regulation.
A. Medina, N. Bodick, A. L. Goldberger, M. M. Mahon, and L. A. Lipsitz (1997)
Hypertension 29, 828-834
   Abstract »    Full Text »
Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease.
A. I. Levey (1996)
PNAS 93, 13541-13546
   Abstract »    Full Text »    PDF »
The treatment of Alzheimer's disease.
N.H.P. Allen and A. Burns (1995)
J Psychopharmacol 9, 43-56
   PDF »
Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia.
W. Samuel, R. D. Terry, R. DeTeresa, N. Butters, and E. Masliah (1994)
Arch Neurol 51, 772-778
   Abstract »    PDF »
The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.
S. E. Molchan, A. M. Mellow, J. L. Hill, H. Weingartner, R. Martinez, B. Vitiello, and T. Sunderland (1992)
J Psychopharmacol 6, 489-500
   Abstract »    PDF »
The Distribution of Cerebral Muscarinic Acetylcholine Receptors In Vivo in Patients With Dementia: A Controlled Study With 123IQNB and Single Photon Emission Computed Tomography.
D. R. Weinberger, R. Gibson, R. Coppola, D. W. Jones, S. Molchan, T. Sunderland, K. F. Berman, and R. C. Reba (1991)
Arch Neurol 48, 169-176
   Abstract »    PDF »
D1-Dopamine Receptor Abnormality in Frontal Cortex Points to a Functional Alteration of Cortical Cell Membranes in Alzheimer's Disease.
J. De Keyser, G. Ebinger, and G. Vauquelin (1990)
Arch Neurol 47, 761-763
   Abstract »    PDF »
Research in Alzheimer's disease: A progress report.
M. B. Moss (1988)
American Journal of Alzheimer's Disease and Other Dementias 3, 10-16
   PDF »
Anticholinergic Sensitivity in Patients With Dementia of the Alzheimer Type and Age-Matched Controls: A Dose-Response Study.
T. Sunderland, P. N. Tariot, R. M. Cohen, H. Weingartner, E. A. Mueller III, and D. L. Murphy (1987)
Arch Gen Psychiatry 44, 418-426
   Abstract »    PDF »
Muscarinic Agonist Therapy of Alzheimer's Disease: A Clinical Trial of RS-86.
G. Bruno, E. Mohr, M. Gillespie, P. Fedio, and T. N. Chase (1986)
Arch Neurol 43, 659-661
   Abstract »    PDF »
Muscarinic Acetylcholine Receptors in Alzheimer's Disease: In Vivo Imaging With Iodine 123--Labeled 3-Quinuclidinyl-4-Iodobenzilate and Emission Tomography.
B. L. Holman, R. E. Gibson, T. C. Hill, W. C. Eckelman, M. Albert, and R. C. Reba (1985)
JAMA 254, 3063-3066
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)